A reverse passive hemagglutination inhibition (RPHI) test was developed for detecting rotavirus antibody in patients' sera. Sheep erythrocytes coated with guinea pig antibody against Nebraska calf diarrhea virus (NCDV) were readily hemagglutinated by NCDV in a reaction called reverse passive hemagglutination (RPHA). Inhibition of this RPHA reaction was used to detect the presence of rotavirus antibody in patients' sera which cross-reacted with NCDV. The sensitivity of RPHI was consistently at least 10 times greater than that of the complement fixation test for detection of rotavirus antibody in patients' sera. Since immunoglobulin M (IgM) antibody activity detected by RPHI was destroyed by pretreatment of serum with dithiothreitol (DDT), whereas DTTresistant antibodies such as IgG remained unchanged, the titer of IgM antibody could be distinguished from that of DTT-resistant antibody by comparing the results of two RPHI tests performed with and without DTT pretreatment. From the IgM antibody response pattern, primary and secondary rotavirus infections could be distinguished.
A reverse passive hemagglutination inhibition (RPHI) test was developed for detecting rotavirus antibody in patients' sera. Sheep erythrocytes coated with guinea pig antibody against Nebraska calf diarrhea virus (NCDV) were readily hemagglutinated by NCDV in a reaction called reverse passive hemagglutination (RPHA). Inhibition of this RPHA reaction was used to detect the presence of rotavirus antibody in patients' sera which cross-reacted with NCDV. The sensitivity of RPHI was consistently at least 10 times greater than that of the complement fixation test for detection of rotavirus antibody in patients' sera. Since immunoglobulin M (IgM) antibody activity detected by RPHI was destroyed by pretreatment of serum with dithiothreitol (DDT), whereas DTTresistant antibodies such as IgG remained unchanged, the titer of IgM antibody could be distinguished from that of DTT-resistant antibody by comparing the results of two RPHI tests performed with and without DTT pretreatment. From the IgM antibody response pattern, primary and secondary rotavirus infections could be distinguished.
Human rotavirus (HRV) has been shown to be a serious etiological agent in infants (2, 7, 10, 21) . Since HRV does not grow efficiently in in vitro culture systems (19) , it has not been possible to detect HRV antibody by conventional neutralization test methods. HRV antibody in sera or milk of patients with HRV infection has been estimated by immunoelectron microscopy (IEM) (8) , complement fixation (CF) (3, 5, 6, 9) , immunofluorescent-antibody techniques (13, 15) , hemagglutination inhibition (11) , enzymelinked immunosorbent assay (20) , and radioimmunoassay (4, 16) . To detect HRV antibody of all classes, antigen absorption tests would be useful. To detect the absorption of HRV by antibody in test material, we applied a reverse passive hemagglutination (RPHA) test, which is a highly sensitive and simple method for detection of rotavirus antigen, as reported previously (17) . By the RPHA inhibition (RPHI) test, antibody activity was successfully detected with a sensitivity sufficient for diagnostic and epidemiological investigations.
MATERIALS AND METHODS
Patients' sera. Sera were obtained from infants admitted to Tachikawa Kyosai Hospital for gastroenteritis who had HRV in their feces. Sera from influenza patients were obtained from pupils of a junior high school. They were diagnosed as having influenza infection either by virus isolation or by serological diagnosis. Healthy adult sera were collected from volunteers in our laboratories.
Virus. Nebraska calf diarrhea virus (NCDV; calf rotavirus) was propagated in MA-104 cells and purified as described previously (18) . This procedure involved rate zonal centrifugation using sucrose and Metrizamide. The resultant virus-containing bands were further purified by a floating method in a Metrizamide gradient at an ultracentrifugation speed of 36,000 rpm for 16 negative-pressure ultrafiltration. A total of 3.99 mg of specific NCDV antibody was recovered from 3.5 ml of the antiserum.
Preparation of Ab-SRBC. Sheep erythrocytes (SRBC) were fixed with 0.5% glutaraldehyde at room temperature for 1 h and then washed with PBS. The fixed SRBC (2.5% suspension) were treated with tannic acid (30 ,ug/ml) at 37°C for 10 min. After washing with saline, a 2.5% suspension of the tanned SRBC was prepared in Mcllvain buffer containing 0.5 M NaCl (pH 5.0). The tanned SRBC in this buffer were mixed with an equal volume of NCDV antibody purified by affinity chromatography (40 ,ug/ml) in the buffer, and the mixture was incubated at room temperature for 1 h to prepare NCDV antibody-sensitized SRBC (Ab-SRBC). Ab-SRBC were washed with PBS, and a 0.6% Ab-SRBC suspension was prepared in PBS containing 2% heat-inactivated rabbit serum (PBS-RS).
Preparation of IgM and IgG antibody fractions of patients' sera. Sera were diluted threefold in saline and incubated in 56°C for 30 min. Then 0.5 ml of the sera was layered on top of 4.5-ml sucrose density gradients (12.5 To absorb antibodies against SRBC from test sera, 100 ,ul of serum to be examined was mixed with 400 ,ul for a 1% suspension of glutaraldehyde-fixed SRBC in PBS and incubated at 37°C for 30 min. The mixture was then centrifuged at 600 x g for 5 min. The supernatant fluid was used as a specimen for RPHI examination. The RPHI test was carried out on a microtitration plate with V-shaped wells (Nihon Microtec Co. Ltd., Tokyo). Serial twofold dilutions of the specimens were made in duplicate in PBS-RS using 25-p.l loops. To one dilution series was added 2 hemagglutination units (HAU) (1 HAU being the minimum amount of antigen causing hemagglutination of Ab-SRBC) of NCDV in 25 p.l. In the counterpart dilution series, 25 pL. of PBS-RS was added to each well to confirm the absence of nonspecific agglutination which might interfere with interpretation. The mixtures were incubated for 1 h at 37°C, and then 25 p.1 of 0.6% Ab-SRBC in PBS-RS was added to each well. After shaking with a vibrator (Nihon) for about 20 s, the microtitration plate was kept at room temperature for 1 h. The RPHI titer of the test serum was considered to be the highest dilution of test serum which completely inhibited hemagglutination. Since the test sera had been previously absorbed with SRBC, no (12) . To each well of serial twofold dilutions of the sera on a Ushaped microtitration plate (Nihon) was added 4 U of NCDV in 25 ,ul (1 U of virus being the minimum amount of virus which induced a positive IAHA pattern in the presence of an optimal amount of HRV antibody and guinea pig complement), and the plate was incubated at 37°C for 1 h. Then 25 of complement was added, and the culture was incubated at 37°C for 40 min. Thereafter dithiothreitol (DTT; 3 mg/ml; Eisai Co. Ltd., Tokyo) and human erythrocytes (type 0) were added. DTT was added to prevent C3b molecules deposited on virus from being inactivated by C3b inactivators (14) .
IEM. Ten microliters of serum diluted fivefold in PBS and 10 of PBS with or without DTT (3 mg/ml) were mixed and incubated for 30 min at 37°C. After incubation, 20 of NCDV (approximately 3 x 109 particles/ml) was added to the mixture, which was incubated further for 1 h at 37°C. A few microliters of the mixture was put on a grid and permitted to settle at room temperature for a few minutes. Then the grid was washed with distilled water, and the materials adsorbed to the grid film were negatively stained with 2% phosphotungstic acid. The specimen was examined with a JEM-1OOB JEOL microscope.
RESULTS
Serum samples collected from patients with infantile gastroenteritis, patients infected with influenza virus, and healthy adults were subjected to HRV antibody titrations by CF, IAHA, and RPHI tests (Table 1 ). In patients with infantile gastroenteritis, RPHI detected antibody in all patients as did CF, except for patient 5 hemagglutination of Ab-SRBC with serially diluted HRV was examined (Fig. 2) . NCDV was diluted in PBS-RS containing different amount of DTT (25 uI/well) and incubated for 30 min at 37°C; then 25 RI of 0.6% Ab-SRBC in PBS-RS was added to each well. In the absence of DTT, RPHA occurred up to a 1:1,024 dilution of antigen. The RPHA reaction remained unchanged in the presence of up to 3 mg of DTT per ml (final concentration before Ab-SRBC addition). Therefore, antigenicity of NCDV and antibody activity fixed on Ab-SRBC was stable to less than 3 mg of DTT per ml, although treatment of NCDV with 6 mg/ml or more sup1gM pressed the agglutinability with Ab-SRBC. Since the treatment of Ab-SRBC with 6 mg of DTT per ml at 37°C for 30 min did not reduce the hemagglutinability with NCDV (data not shown), the suppression of antigen titer by pretreatment of NCDV with this DTT concentration might have been due to the decrease of reactivity of NCDV with Ab-SRBC.
The effect of DTT on HRV IgM and IgG fractions prepared from patients' sera by sucrose density gradient ultracentrifugation was examined (Fig. 3) Days after Onset antibody (25 ,ulIwell) were incubated at 37°C for 30 min, and 2 HAU of NCDV in 25 ,uzl was added to each well. After incubation at 37°C for 1 h, 25 ,ul of 0.6% Ab-SRBC was added to examine the DTT-treated antibody activity by RPHI. HRV IgM antibody lost reactivity after incubation with 1.5 mg of DTT per ml, whereas HRV antibody activity in IgG fractions remained unchanged even after incubation with 3 mg/ml (Fig.   3 ). In the experiment where antibodies were treated with 6 mg of DTT per ml or more, the effect of DTT on HRV antibody activity could not be determined by RPHI, since the high dose of DTT alone inhibited the reactivity of 2 HAU of NCDV (Fig. 2) .
Patients' sera were fractionated by sucrose density gradient ultracentrifugation and examined for antibody activity by RPHI with or without pretreatment with 1.5 mg of DTT per ml at 37°C for 30 min (Fig. 4) . Before the DTT treatment, RPHI antibody was detected in the fractions (from 3 to 6) prepared from patient serum (patient 1) obtained 9 days after the onset of disease. However, no antibody activity was detected in these fractions after preincubation with DTT. Furthermore, fractions from 3 to 6 proved to be the fraction of ugM by SRID. In the case of patient 13 (Fig. 5) , RPHI antibody activity was detected in the fractions from 2 to 15.
After pretreatment with DTT, the reactivity of the fractions from 2 to 5 was lost, whereas that of the fractions from 7 to 14 remained unchanged. SRID (Table 1) . DTT-resistant antibody was not detected at the early stage after the onset of disease except in patient 13. DTT-resistant antibody appeared at the 5th day after onset. This kind of IgM antibody response presumably occurs in a primary infection with HRV. In patient 13, DTT-resistant antibody activity was detected as early as the 1st day after the onset of the disease, and the antibody activity increased remarkably at the 8th day. This finding indicates that patient 13 was probably reinfected with HRV. All sera from patients diagnosed as having influenza virus infection, as well as healthy adults, had antibody activity, and essentially no reduction of the antibody activity by DTT treatment was noted. They were considered to have a history of past HRV infection.
DTT-treated and nontreated sera were mixed with HRV and observed by IEM (Fig. 6) . In all cases, nontreated sera agglutinated the virus; however, DTT-treated sera from patients 11 (day 6) and 12 (day 6) lost the ability to agglutinate the virus. However, DTT-treated serum from healthy adult 24 agglutinated the virus, as did the nontreated serum. DISCUSSION NCDV can easily propagate in cell culture, and some antigens of NCDV are shared with those of HRV. Therefore, to detect HRV antibody by CF, NCDV has been used instead of HRV (6) . In this report we also used NCDV to detect HRV antibody in patients' sera by inhibition of NCDV to agglutinate Ab-SRBC. Since the HRV antibody in patients' sera reacts with NCDV added to the reaction mixture, NCDV lost the ability to agglutinate the Ab-SRBC. This method will detect all classes of antibodies to HRV which cross-react with NCDV. The method will also detect non-CF antibodies which can not be detected by CF or IAHA tests. Within 17 days after the onset of disease (except for one patient), IAHA antibody was not detectable, although CF and RPHI antibody were detected later than 6 and 2 days, respectively, after the onset of disease. Therefore, the IAHA method is not appropriate for the detection of anti-HRV in sera during the early stage of HRV infection.
When NCDV was reacted with serum antibody, agglutination of the virus particles occurred (Fig. 7) . This virus agglutination decreased the number of particles below the number required to cause hemagglutination of Ab-SRBC. Although antibodies in patients' sera VOL. 15, 1982 on (10 ,ul) was mixed with DTT-PBS (3 mg/ml) or PBS (10 ,ul) and incubated at 37°C for 30 min. Then NCDV (20 ,u1) was added to the mixture, which was incubated at 37°C for 1 h. The mixture was negatively stained with 2% phosphotungstic acid.
J. CLIN. MICROBIOL.
on November 2, 2017 by guest http://jcm.asm.org/ Downloaded from might not have neutralized all antigenic sites on NCDV, they produced RPHI because they could agglutinate NCDV. Since preincubation of IgM antibody with 1.5 mg of DTT per ml at 37°C for 30 min completely abolished its RPHI activity, whereas IgG fractions retained activity (Fig.  3) , IgM antibody could be easily differentiated from other DTT-resistant antibodies such as IgG. When the patients' sera from early stages of HRV infection were treated with DTT, the activity of RPHI and agglutinability with NCDV as determined by electron microscopy were decreased. DTT-treated anti-HRV of the IgM type may have failed to produce RPHI because the treated IgM antibody lost the ability to agglutinate NCDV (Fig. 7) . Since virus particles reacted with DTT-treated IgM antibody remained unagglutinated, they may have been able to react with Ab-SRBC through the antigenic sites which had not been blocked by the DTT-treated, monovalent IgM antibody. When patients' sera from late stages of HRV infection, or sera from healthy adults, were treated with DTT, their RPHI activity and agglutinability with NCDV were not decreased. The presence of DTTresistant antibody in healthy adults indicated that they had been exposed to HRV and were producing IgG-type antibodies.
Influenza virus was isolated from patient 14, and seroconversion against HRV was demonstrated for this patient by CF, IAHA, and RPHI tests. Therefore, the patient was assumed to be infected with HRV in addition to influenza virus. This was probably a reinfection with HRV as occurred in patient 13, since in early sera from this patient, DTT-resistant RPHI antibody was already positive and the titer increased thereafter. Thus, results of RPHI with and without DTT pretreatment can suggest whether a patient has a primary infection or reinfection of HRV.
